Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Gut microbiota and NASH course
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Gut microbiota and NASH course
Gastroenterology

Gut microbiota and NASH course

Hepatitis
Hepatology Gastroenterology

A study recently demonstrated a link between gut microbiota and inflammatory state that promotes progression of non-alcoholic fatty liver disease to steatohepatitis through the production of short-chain fatty acids.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail
Photo : Gut microbiota and NASH course

About this article

Created 26 March 2019
Updated 06 October 2021

Together with insulin resistance, non-alcoholic fatty liver disease (NAFLD) has become the most frequent hepatic disorder in Western countries, with a prevalence of around 25%. The first stage is fatty liver disease, which progresses to non-alcoholic steatohepatitis (NASH) in some patients under the influence of several factors, including a proinflammatory state. A German team recently published a study comparing three parameters from 32 patients with NAFLD (of which 18 with NASH) and 27 healthy volunteers: gut microbiota, fecal short-chain fatty acids (SCFA) and Th17/rTreg ratio in blood.

NASH-specific microbiota

Compared to patients with a less advanced stage of non-alcoholic fatty liver disease, those with NASH have a greater abundance of species from the Fusobacteriaceae family and Fusobacterium, Prevotella and Eubacterium genera, as well as a higher content of Fusobacteriaceae and Prevotellacea, two bacterial groups that probably produce SCFAs, compared to control subjects. The observed microbiotic profile thus characterizes two different subgroups corresponding to patients with or without NASH in the NAFLD group, and it is correlated to the results of hepatic biopsies. This could open the way to a new non-invasive method to monitor the disease, since hepatic biopsy is currently the only way to diagnose NASH. Moreover, fecal levels of acetate, propionate and butyrate–three SCFAs produced by the fermentation of dietary fiber in the GI tract–are higher in the NAFLD group than in the control group. A significantly higher level of butyrate is also observed in the NASH group compared to the control group.

The controversial role of SCFAs

Finally, the study focused on the comparison between levels of specific blood lymphocytes: anti-inflammatory resting Treg cells (rTreg) and pro-inflammatory Th17 cells. A study published by the same team had shown that the Th17/rTreg ratio was higher in the NASH subgroup than in patients with NAFLD. The current study brought to light a positive correlation between Th17/rTreg ratio and fecal levels of acetate and propionate. SCFAs are also known for their anti-inflammatory properties, but several studies, including this one, have raised the question of their proinflammatory role in some pathologies and under certain conditions.

Sources

Rau et al., Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease, United European Gastroenterology Journal 2018, Vol. 6(10) 1496–1507

He et al., The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice, BMC Immunol. 2017; 18: 33

Yoon et al., Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease, World J Hepatol. 2014 Nov 27;6(11):800-11

Gariani et al., Diabète et stéatose hépatique non alcoolique, Rev Med Suisse 2012 Jun 6;8(344):1211-4.

Tags
NASH Predicator SCFA Non-alcoholic fatty liver disease Short-chain fatty acid Inflammation Insulin

en_view en_sources

    Created 26 March 2019
    Updated 06 October 2021

    About this article

    To know more about this topic.

    Main topic

    Hepatitis

    Medical practice

    Hepatology Gastroenterology

    Content type

    News
    Gastroenterology

    Probiotics: what exactly are we talking about?

    From the Latin pro and Greek bios meaning “for life”, the term “probiotic” was suggested over 60 years ago,...

    Find out more

    How do you choose a probiotic for your patient?

    Faced with a plethora of products on the market, it's not always easy for health professionals to suggest a...

    Find out more

    Gut microbiota and Clostridioides difficile

    Overview By Pr. Gianluca IaniroDigestive Disease Center, Fondazione Policlinico “A. Gemelli” IRCCS, Rome, ...

    Find out more

    Impact of antibiotics on the gut microbiota, does it matter?

    Overview By Pr. Francisco GuarnerDigestive System Research Unit, University Hospital Vall d’Hebron, Barcel...

    Find out more

    From diarrhea to chronic diseases: the well-documented consequences of antibiotic-related gut microbiota dysbiosis

    Antibiotic treatment may sometimes take place without any...

    Find out more

    Resilience of healthy adult gut microbiota following antibiotic exposure

    Commented articles - Adults' section By Pr. Harry SokolG...

    Find out more

    Antibiotic resistance: the lung microbiota pays a heavy price

    Broad-spectrum antibiotics used for treating lung infections are regarded as one of the principal contribut...

    Find out more

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    Continue reading

    News
    23.11.2022

    Is gut dysbiosis a risk factor for HIV infection?

    Read the article
    22.11.2023

    Is vaginal microbiota transfer the new miracle for C-section babies?

    Read the article
    26.10.2023

    Can antibiotics promote the growth of harmful bacteria in the gut?

    Read the article
    Intestinal bacteria, illustration.
    24.08.2023

    Everything you need to know about probiotics

    Read the article
    20.10.2023

    Fecal transplant: “where, when, how much” needed to optimize effects on IBS?

    Read the article
    26.07.2023

    Unexpected effect of famous antibiotic on fungal microbiota

    Read the article
    29.08.2023

    Massive amounts of antibiotic resistance genes found in clouds

    Read the article
    Antibiotiques : le mycobiote des nourrissons sous influence
    16.08.2022

    The effect of antibiotics on infant mycobiota

    Read the article
    What's worth reading about microbiota
    Follow us on X
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    Microbiota 17 EN
    Check out our latest magazine
    The first 1000 days of life
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    27.11.2023

    Predicting the risk of preterm birth through vaginal microbiota

    Read the article

    Antimicrobial resistance: Doctor, your role is essential! Patient, your behavior is key!

    In November, Biocodex and the Biocodex Microbiota Institu...

    Find out more
    22.11.2023

    Is vaginal microbiota transfer the new miracle for C-section babies?

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo